Cellceutix’s lead compound Kevetrin is indicated for the treatment of drug-resistant cancers.
The company is currently finalizing and reviewing all investigational new drug (IND) documentation for submission to the US Food and Drug Administration, in May 2011.
Cellceutix CEO Leo Ehrlich said their lead compound Kevetrin has a unique chemical structure; the first in its class of chemistry to be used as an anti-cancer agent.
"Should we achieve proper efficacy during the planned clinical trials, we hope that the FDA may grant Accelerated Approval or Priority Review for Kevetrin," Ehrlich said.